NEC
NEC Corporation (TOKYO: 6701) today announced a collaboration with Siemens in the IoT field to provide a monitoring and analysis solution for manufacturing that connects MindSphere®, the cloud-based, open Internet of Things (IoT) operating system from Siemens, and NEC's System Invariant Analysis Technology (SIAT). As part of the agreement, NEC is joining the MindSphere Partner Program, which can provide NEC with access to specialized technical training and support from Siemens as well as a number of joint go-to-market capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200308005027/en/
In recent years, with the acceleration of digitization and the spread of IoT, the safety, efficiency, maintenance and product quality of systems are being visualized and analyzed based on data collected from a large number of sensors installed in various locations, such as plant systems, manufacturing lines and factories. However, it is necessary to systemize data collection, storage, monitoring, analysis and other processes in order to utilize sensor data. Moreover, unique know-how, such as knowledge about IoT systems and data analysis, is required to construct such a system, making it difficult for customers to construct by themselves.
In addition, especially in the manufacturing industry, work processes are often based on the expertise of each plant or individual. Therefore, the loss of know-how due to the retirement of skilled personnel and lack of staff poses a serious challenge.
In order to solve these issues, NEC and Siemens have enhanced their products to enable greater visualization and analysis of sensor data.
System Invariant Analysis Technology, part of NEC's cutting-edge portfolio of AI technologies, "NEC the WISE", is being used to automatically learn and model the behavior of systems based on data gathered from a large number of sensors installed in large-scale, complex systems. This provides visualization of systems and how they operate, in addition to enabling systems to operate safely and efficiently by proactively detecting errors using analytical models. NEC has already installed approximately 100 such systems internationally.
MindSphere is the cloud-based, open IoT operating system from Siemens that connects products, plants, systems, and machines, enabling companies to harness the wealth of data generated by the IoT with advanced analytics. The MindSphere Partner Program is Siemens’ partner program for industrial IoT solution and technology providers.
This collaboration enables both companies to provide total data collection, storage, monitoring and analysis, including customization according to customer needs. Specifically, MindSphere is being used to collect and accumulate field sensor data and NEC's System Invariant Analysis Technology system automatically monitors and analyzes the data. This solution will first be offered as a cloud solution for the manufacturing industry, then applied to factory systems, manufacturing lines, plant facilities and other equipment, as well as products that are produced using this equipment. This makes it easy to visualize and analyze vast amounts of sensor data, thereby contributing to increased productivity, reduced operational risk, product quality and the preservation of know-how.
The companies plan to target customers in manufacturing industries internationally, then expand to customers in other industries.
"It is an honor to collaborate with Siemens to enhance the productivity of the manufacturing industry through System Invariant Analysis Technology,” said Osamu Fujikawa, Senior Vice President, NEC Corporation. “NEC will accelerate the digitization of enterprises through the provision of solutions worldwide that leverage both companies’ strengths. NEC will continue to address diversifying needs by fusing real and digital technologies as well as by leveraging advanced technologies such as AI and IoT,” he added.
"Siemens is committed to creating partnerships that help customers realize digital transformation with Industrial IoT. Working with NEC can help provide MindSphere applications that improve customers’ ability to add value to their digital transformation initiatives,” said Kunihiko Horita, Japan Country Manager, Siemens Digital Industries Software.
About NEC Corporation:
For more information, visit NEC at www.nec.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200308005027/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom